Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Baxter
Dow
Harvard Business School
Medtronic
Express Scripts
Merck

Last Updated: June 30, 2022

CLINICAL TRIALS PROFILE FOR ACIPHEX


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Aciphex

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00204672 ↗ The Role of GER in Exercise Triggered Asthma Completed PriCara, Unit of Ortho-McNeil, Inc. Phase 2/Phase 3 2000-10-01 HYPOTHESIS Gastroesophageal reflux is a major contributor to exercise-triggered asthma. Two groups of patients will be studied: those with asthma who have difficulty with exertion, those without asthma who experience difficulty with exertion. Both groups will experience gastroesophageal reflux (GER) twice of less per week. Patients will complete a treadmill exam to determine their VO2 max. They will then undergo pH monitoring while exercising for 30 minutes at 65-70% of their VO2 max. Subjects will be given placebo or acid suppression pill for 12 weeks. At the end of 12 weeks, the subjects will repeat the exercise (30 minutes) and 24-hour pH study.
NCT00204672 ↗ The Role of GER in Exercise Triggered Asthma Completed University of Utah Phase 2/Phase 3 2000-10-01 HYPOTHESIS Gastroesophageal reflux is a major contributor to exercise-triggered asthma. Two groups of patients will be studied: those with asthma who have difficulty with exertion, those without asthma who experience difficulty with exertion. Both groups will experience gastroesophageal reflux (GER) twice of less per week. Patients will complete a treadmill exam to determine their VO2 max. They will then undergo pH monitoring while exercising for 30 minutes at 65-70% of their VO2 max. Subjects will be given placebo or acid suppression pill for 12 weeks. At the end of 12 weeks, the subjects will repeat the exercise (30 minutes) and 24-hour pH study.
NCT00204698 ↗ Laryngopharyngeal Reflux and Proton Pump Inhibitor (PPI) Treatment Completed PriCara, Unit of Ortho-McNeil, Inc. Phase 2/Phase 3 2003-08-01 This study proposes to investigate prospectively, the presence of molecular markers for inflammation in laryngopharyngeal reflux (LPR) patients and to study the effect of a proton pump inhibitor (Aciphex) on these molecular markers. The investigators will be evaluating a group of patients before and after treatment. This group will be patients that have untreated laryngopharyngeal reflux diagnosed by laryngoscopic assessment and a 24-hour probe.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Aciphex

Condition Name

Condition Name for Aciphex
Intervention Trials
Healthy 7
Gastroesophageal Reflux Disease (GERD) 6
Heartburn 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Aciphex
Intervention Trials
Gastroesophageal Reflux 12
Esophagitis, Peptic 7
Heartburn 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Aciphex

Trials by Country

Trials by Country for Aciphex
Location Trials
United States 55
Japan 24
India 16
Germany 13
Argentina 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Aciphex
Location Trials
Illinois 5
California 5
North Dakota 4
New York 3
Connecticut 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Aciphex

Clinical Trial Phase

Clinical Trial Phase for Aciphex
Clinical Trial Phase Trials
Phase 4 1
Phase 3 8
Phase 2/Phase 3 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Aciphex
Clinical Trial Phase Trials
Completed 21
Terminated 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Aciphex

Sponsor Name

Sponsor Name for Aciphex
Sponsor Trials
Eisai Inc. 9
Mylan Pharmaceuticals 3
Torrent Pharmaceuticals Limited 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Aciphex
Sponsor Trials
Industry 23
Other 5
U.S. Fed 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Colorcon
McKesson
Mallinckrodt
Merck
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.